Synergistic anti-tumor effect of 13-cRA and IFN-α/β in mouse renal cell carcinoma

International Journal of Oncology

Volumn 13, Issue 1, 1998, Pages 145-149

  Taguchi, Isao ^a   Hara, Isao ^a   Gohji, Kazuo ^a   Arakawa, Soichi ^a   Kamidono, Sadao ^a  

^a KOBE UNIVERSITY   (Japan)

Author keywords

13 cis retinoic acid; Interferon ; Renal cell carcinoma

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; ISOTRETINOIN; MESSENGER RNA; RETINOIC ACID RECEPTOR;

ANIMAL CELL; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG POTENTIATION; FEMALE; KIDNEY CARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, RENAL CELL; DRUG SYNERGISM; FEMALE; INTERFERON-ALPHA; INTERFERON-BETA; ISOTRETINOIN; KIDNEY NEOPLASMS; LUNG NEOPLASMS; MICE; MICE, INBRED BALB C; RECEPTORS, RETINOIC ACID; RNA, MESSENGER; TUMOR CELLS, CULTURED;

EID: 0031860552     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Bassil B, Dosoretz E and Prout GR Jr: Validation of the tumor, nodes and metastasis classification of renal cell carcinoma. J Urol 134: 450-454, 1985.
2. Quesada JR, Swanson DA, Trindade A and Gutterman JU: Renal cell carcinoma: Antitumor effects of leukocyte interferon. Cancer Res 43: 940-947, 1983.
3. Wirth MP: Immunotherapy for metastatic renal cell carcinoma. Urol Clin North Am 20: 283-295, 1993.
4. Horoszewicz JS and Murphy GP: An assessment of the current use of human interferons in therapy of urological cancers. J Urol 142: 1173-1180, 1989.
5. Rosenberg S: The development of new immunotherapies for the treatment of cancer using interleukin-2: A review. Ann Surg 208: 889-897, 1988.
6. Kinouchi T, Saiki S, Maeda O, Kuroda M, Usami M and Kotake T: Treatment of advanced renal cell carcinoma with a combination of human lymphoblastoid interferon-alpha and cimetidine. J Urol 157: 1604-1607, 1997.
7. Smith MA, Parkinson DR, Cheson BD and Friedman MA: Retinoids in cancer therapy. J Clin Oncol 10: 839-864, 1992.
8. Castaigne S, Chomienne C, Daniel MT, Ballerini P, Berger R, Fenaux P and Degos L: All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I. Clinical results. Blood 76: 1704-1709, 1990.
9. Hong WK, Lippman SM, Itri LM, Karp DD, Lee JS, Byers RM, Schantz SP, Kramer AM, Lotan R, Peters LJ, Dimery IW, Brown BW and Goepfert H: Prevention of second primary tumors with isotretinoin in sqamous-cell carcinoma of the head and neck. N Engl J Med 323: 795-801, 1990.
10. Tobler A, Munker R, Heitjan D and Koeffler HP: In vitro interaction of recombinant tumor necrosis factor alpha and all-trans-retinoic acid with normal and leukemic hematopoietic cells. Blood 70: 1940-1946, 1987.
11. Fontana J: Interactions of retinoids and tamoxifen on the inhibition of human mammary carcinoma cell proliferation. Exp Cell Biol 55: 136-144, 1987.
12. Lotan R, Dawson MI, Zou CC, Jong L, Lotan D and Zou CP: Enhanced efficacy of combinations of retinoic acid- and retinoid X receptor-selective retinoids and α-interferon in inhibition of cervical carcinoma cell proliferation. Cancer Res 55: 232-236, 1995.
13. Marth C, Daxenbichler G and Dapunt O: Synergistic anti-proliferative effect of human recombinant interferons and retinoic acid in cultured breast cancer cells. J Natl Cancer Inst 77: 1197-1202, 1986.
14. Lippman SM, Kavanagh JJ, Paredes-Espinoza M, Delgadillo-Madrueno F, Paredes-Casillas P, Hong WK, Holdener E and Krakoff IH: 13-cis-retinoic acid plus interferon α-2a: Highly active systemic therapy for squamous cell carcinoma of cervix. J Natl Cancer Inst 84: 241-245, 1992.
15. Lippman SM, Parkinson DR, Itri LM, Weber RS, Schantz SP, Ota DM, Schusterman MA, Krakoff IH, Gutterman JU and Hong WK: 13-cis-retinoic acid plus interferon α-2a: Effective combination therapy for advanced squamous cell carcinoma of the skin. J Natl Cancer Inst 84: 235-241, 1992.
16. Motzer RJ, Schwartz L, Law TM, Murphy BA, Hoffman AD, Albino AP, Vlamis V and Nanus DM: Interferon alfa-2a and 13-cis-retinoic acid in renal cell carcinoma: Antitumor activity in a phase II trial and interaction in vitro. J Clin Oncol 13: 1950-1957, 1995.
17. Miyake H, Hara I, Yoshimura K, Eto H, Arakawa S, Wada S, Chihara K and Kamidono S: Introduction of basic fibroblast growth factor gene into mouse renal cell carcinoma cell line enhances its metastatic potential. Cancer Res 56: 2440-2445, 1996.
18. Aapro MS, Alberts DS and Salmon SE: Interactions of human leukocyte interferon with Vinca alkaloids and other chemotherapeutic agents against tumors in clonogenic assay. Cancer Chemother Pharmacol 10: 161-166, 1983.
19. Chomoczynski P and Sacchi N: Single-step method of RNA isolation by guanidium thiocyanate-chloroform extraction. Anal Biochem 162: 156-159, 1987.
20. Tanji N, Yokoyama M, Takeuchi M, Terada N, Dahiya R and Cunha GR: Inhibitory effects of retinoic acids on androgen dependent development of neonatal mouse seminal vesicles in vitro. Endocrinology 137: 2887-2895, 1996.
21. Mangelsdorf DJ, Ong ES, Dyck JA and Evans RM: Nuclear receptor that identifies a novel retinoic acid response pathway. Nature 345: 224-229, 1990.
22. Krust A, Kastner P, Petkovich M, Zelent A and Chambon P: A third human retinoic acid receptor, hRAR-γ. Proc Natl Acad Sci USA 86: 5310-5314, 1989.
23. Zelent A, Krust A, Petkovich M, Kastner P and Chambon P: Cloning of murine α and β retinoic acid receptors and a novel receptor γ predominantly expressed in skin. Nature 339: 714-717, 1989.
24. Widschwendter M, Daxenbichler G, Bachmair F, Müller E, Zeimet AG, Windbichler G, Uhl-Steidl M, Lang T and Marth C: Interaction of retinoic acid and interferon-α in breast cancer cell lines. Anticancer Res 16: 369-374, 1996.
25. Wahlberg P, Einarsdottir M, Fex G and Rydell R: The additive antiproliferative effect of all-trans retinoic acid and interferon-α2a on human cervical carcinoma cell lines is not associated with increased expression of retinoid receptors. Anticancer Drugs 8: 522-528, 1997.
26. Takase S, Ong DE and Chytil F: Transfer of retinoic acid from its complex with cellular retinoic acid-binding protein to the nucleus. Arch Biochem Biophys 247: 328-334, 1986.
27. Boylan JF and Gudas LJ: Overexpression of the cellular retinoic acid binding protein-I (CRABP-I) results in a reduction in differentiation-specific gene expression in F9 teratocarcinoma cells. J Cell Biol 112: 965-979, 1991.
28. Lancillotti F, Giandomenico V, Affabris E, Fiorucci G, Romeo G and Rossi GB: Interferon α-2b and retinoic acid combined treatment affects proliferation and gene expression of human cervical carcinoma cells. Cancer Res 55: 3158-3164, 1995.
29. Kolla V, Lindner DJ, Weihua X, Borden EC and Kalvakolanu DV: Modulation of interferon (IFN)-inducible gene expression by retinoic acid. J Biol Chem 271: 10508-10514, 1996.